Less Ads, More Data, More Tools Register for FREE

Pin to quick picksAngle Regulatory News (AGL)

  • There is currently no data for AGL

New Contracts

12 Apr 2005 07:00

Angle PLC12 April 2005 For Immediate Release Tuesday 12 April 2005 ANGLE plc ANGLE Signs Three Year Management Contract with Qatar's Science & Technology Park ANGLE plc, the venture management and consulting company specialising in thecommercialisation of technology, is pleased to announce that it has beenappointed to manage Qatar's Science & Technology Park ("STP") until March 2009. ANGLE will provide the Qatar Foundation, owner of the Science & Technology Parkin Doha, with a specialised project team, supported by additional staffresources from Europe and the US. The team is charged with ensuring theeffective establishment and operation of the STP, which will be the emerginginternational hub of research and commercialisation in the Middle East. ANGLE will be responsible for leadership on strategic and operationalactivities, management of technology transfer issues, the development of STP'sphysical presence and external profile, as well as programs supporting Qatar'sdevelopment and commercialisation of technology. The value of the contract isover £6 million over the 3 year term. Qatar Foundation's Science & Technology Park aims to be an internationallocation for the development and commercialisation of technology. Part of theone thousand hectare Education City campus in Doha, it is a place wherecompanies can develop their intellectual property and deliver it to themarketplace; where research institutes undertake collaborative R&D; and whereentrepreneurs create and grow start-up technology companies. STP will host companies from a range of sectors and sizes: multinational andlocal companies, start-ups, training and consulting firms, and researchinstitutes. Multinational companies EADS, ExxonMobil, Microsoft, Shell and Totalhave already announced their intention to establish operations at STP. Theyjoin world-class Universities on the campus: Texas A&M University (engineering),Carnegie Mellon (computer science and business), Weill Cornell (medicine) andVirginia Commonwealth University (design). His Excellency Dr Abdulla Al Kubaisi, Chairman of STP and member of the QatarFoundation Board of Directors, commented: "Over the past fifteen months Qatar Foundation has been impressed with ANGLE'sperformance to date in getting Qatar's Science & Technology Park off the ground.We are very confident they will continue this success over the coming years." Andrew Newland, Chief Executive of ANGLE, said: "I am delighted that ANGLE has been selected to deliver the next critical phaseof STP's development. This is an important milestone for our company, placingus at the centre of one of the world's most ambitious technologycommercialisation projects. We will be leading the research andcommercialisation process in Qatar through a raft of STP programmes includingthe creation and growth of new technology companies, establishment of a venturecapital fund, and development of an entrepreneurship training and mentoringprogram. We are pleased to be working with such a high calibre Board ofGovernors." For further information ANGLE plc +44 (0)1483 295830Andrew Newland, Chief ExecutiveDawson Buck, Deputy Chief Executive Buchanan Communications +44 (0)20 7466 5000Richard Darby, James Strong Notes to Editors ANGLE Founded in 1994, ANGLE is an international venture management and consultingcompany focusing on the commercialisation of technology and the development oftechnology-based industry. ANGLE creates, develops and advises technologybusinesses on its own behalf and for its clients. ANGLE is listed on AIM(AGL.L); further information can be found on www.ANGLEplc.com STP Qatar Foundation's Science & Technology Park is creating the ideal environmentin which to develop and commercialise technology. It provides world-classfacilities and services for companies from around the globe, and is fosteringstart-up technology enterprises. Located in Qatar's renowned Education City,STP tenants have access to the region's leading research universities and theirhighly educated graduates. STP will also be one of Qatar's first free-tradezones, making it easy and attractive to set up a wholly-owned company in thecountry. By encouraging local technology development, STP is creatingopportunities for the region's scientists and entrepreneurs, and leading toinnovations that will benefit its industry and society. www.stp.org.qa Her Highness Sheikha Mozah Bint Nasser Al-Missned has appointed an internationalBoard of Governors to the STP chaired by His Excellency Dr Abdulla Al Kubaisi,Director of the Office of Her Highness, Member of the Qatar Foundation Board ofDirectors. Its other members are Professor Sir Graeme Catto, President of theGeneral Medical Council in the UK, Pro Vice-Chancellor University of London,Vice-Principal King's College London, Dean of Guy's, King's and St Thomas'Medical and Dental Schools; Ms Dinah Adkins, President and CEO of the NationalBusiness Incubation Association in the USA; Ms Jill R Felix, former Presidentand CEO of University Science Center in the Philadelphia, USA; Mr Khalid Mannai,Chairman Mannai Corporation, Qatar; Dr Charles Young, President QatarFoundation, formerly President University of Florida and Chancellor ofUniversity of California Los Angeles. THE QATAR FOUNDATION for Education, Science & Community Development is aprivate, non profit, chartered organization, founded in 1995 by His HighnessSheikh Hamad Bin Khalifa Al-Thani, Emir of Qatar, and chaired by Her HighnessSheikha Mozah Bint Nasser Al-Missned. The Foundation's flagship project isEducation City, a 2,500-acre campus on the outskirts of Doha which hosts branchcampuses of four of the world's leading research universities, as well as QatarScience and Technology Park and the RAND-Qatar Policy Institute. Soon it willinclude a specialty teaching hospital and a world-class convention centre. Formore information on the Qatar Foundation and its projects, please visitwww.qf.org.qa. This information is provided by RNS The company news service from the London Stock Exchange
Date   Source Headline
29th Oct 20257:00 amRNS-RCHANGE OF NAME
16th Oct 20257:00 amRNSAppointments: Interim CEO and senior board advisor
8th Oct 20257:00 amRNSStrategy Update
29th Sep 20257:00 amRNS-RPresentation of Data on Glioblastoma
12th Sep 20257:00 amRNSBoard Changes
9th Sep 20257:01 amRNSInterim Results
9th Sep 20257:00 amRNSChange of Adviser
5th Sep 20252:58 pmRNSNotice of Results
20th Aug 20257:00 amRNSANGLE announces collaboration with Myriad Genetics
8th Jul 20257:00 amRNS-RPARSORTIX ENABLES STUDY OF CANCER PROGRESSION
30th Jun 20255:50 pmRNSResult of 2025 Annual General Meeting
17th Jun 20257:00 amRNS-REACR 2025: Innovation in AR expression profiling
17th Jun 20257:00 amRNS-REACR 2025: Data demonstrating DNA dual analysis
10th Jun 20257:00 amRNS-RNovel discoveries into the biology of cancer
9th Jun 20257:00 amRNSPOSTING OF ANNUAL REPORT AND NOTICE OF AGM
6th Jun 20257:00 amRNSBoard Changes
28th May 20257:00 amRNSPreliminary Results
23rd May 20257:00 amRNSNotice of Results
28th Apr 20257:00 amRNS-RRESULTS SUPPORTING ANGLE’S HER2 ASSAY PROGRAMME
21st Mar 20257:00 amRNSIssue of LTIP Options and Share Options
21st Mar 20257:00 amRNSResults of Eisai Phase 2 pilot study
6th Feb 20257:00 amRNS-RNovel findings using Parsortix
29th Jan 20257:00 amRNSAnalysis of CTC-DNA and ctDNA using Illumina assay
24th Jan 202510:05 amRNS-RParsortix used in research paper from ETH Zurich
23rd Jan 20257:00 amRNSTrading Update
26th Sep 20247:00 amRNSHalf-year Report
23rd Sep 20247:00 amRNSExclusive agreement for DNA NGS panel
17th Sep 20247:00 amRNSNotice of Interim Results and Webcast
18th Jul 202410:08 amRNSStandard form for notification of major holdings
12th Jul 20243:38 pmRNSStandard form for notification of major holdings
11th Jul 20243:07 pmRNSResult of 2024 Annual General Meeting
21st Jun 20247:00 amRNSResult of open offer
18th Jun 20242:41 pmRNSPosting of 2023 Annual Report & Notice of the AGM
11th Jun 20247:00 amRNSParsortix and assays being showcased at EACR 2024
6th Jun 20244:37 pmRNSPublication of Circular
5th Jun 20244:04 pmRNSResults of placing and subscription
5th Jun 20247:00 amRNSProposed Placing, Subscription and Open Offer
5th Jun 20247:00 amRNSPreliminary Results
16th May 20247:00 amRNSStudy of ovarian cancer CTCs using Parsortix
3rd May 20247:00 amRNSNew commercial agreement with large pharma
24th Apr 20247:00 amRNSNew commercial agreement with AstraZeneca
22nd Apr 20247:00 amRNSUS and EU patents for innovative CellKeep™ slide
8th Apr 20247:00 amRNSParsortix HER2 assay showcased at AACR 2024
22nd Mar 20247:00 amRNSParsortix at European breast cancer conference
22nd Jan 20247:00 amRNSPotential utility in precision oncology
10th Jan 202412:57 pmRNSStandard form for notification of major holdings
4th Jan 20247:00 amRNSBreakthrough clinical results
2nd Jan 20247:00 amRNSContract announcement with Eisai Inc.
11th Dec 20237:00 amRNSBroker Announcement
11th Dec 20237:00 amRNSParsortix unlocks opportunities for drug discovery

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.